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Leishmaniasis in 
Chaparé, Bolivia
To the Editor: In Bolivia, most 
cases of leishmaniasis are caused by 
Leishmania (Viannia) braziliensis (1). 
The parasite is transmitted zoonoti-
cally by several sandﬂ  y species and, 
when transmitted to humans, may 
cause cutaneous leishmaniasis (CL), 
and potentially, mucosal leishmaniasis 
(ML) (2).
Data on the prevalence and effects 
of CL in Bolivia have been scarce, 
even though anecdotal and ofﬁ  cial 
reports indicate a dramatic increase 
in the number of human CL cases in 
Bolivia in the past decade (1,3). Also, 
although CL was originally a sylvatic 
disease in Bolivia, some evidence 
indicates that the transmission cycle 
has adapted to the peridomestic habi-
tat. However, this evidence is largely 
based on individual case reports. No 
information is available on parasite 
species, vectors, and reservoirs in such 
a peridomestic transmission cycle.
A preliminary study to guide fu-
ture research focus and assist in im-
mediate leishmaniasis prevention and 
control policy decision making is 
underway in Isiboro-Secure National 
Park, Chaparé, Bolivia. Our objec-
tives were to collect data on the preva-
lence of leishmaniasis in that area and 
evidence for peridomestic Leishmania 
transmission.
A survey was carried out during 
April–July 2007 in 2 communities in 
Isiboro-Secure National Park, San Ga-
briel (16°40′31′′S and 65°37′38′′W) 
and San Julian (16°41′59′′S and 
65°38′10′′W). These 2 communities 
were selected because of local knowl-
edge of disease in the community, 
their moderate degree of urbaniza-
tion (i.e., ≈50% of the communities’ 
houses are clustered around the main 
access road), and the accessibility of 
the sites to the ﬁ  eld team. In this area, 
CL is transmitted from April through 
October.
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Households in both communities 
were visited by a team of experienced 
medical staff who interviewed heads 
of household to collect demographic 
data (sex, age) and diagnose the clini-
cal condition of all present household 
members (presence/absence of CL 
lesions or scars, number of lesions, 
date of lesion onset) by using a stan-
dardized, pretested questionnaire. 
The study protocol was approved 
by the Ethical Committee Review 
Board of the World Health Organiza-
tion (WHO). All patients with active 
cases were treated with meglumine 
antimoniate according to the standard 
protocol (2).
We surveyed 133 and 52 house-
holds in San Gabriel and San Julian, 
which represented 86% and 80% of 
the total households of the respective 
communities; 21 and 13 households, 
respectively, were visited but did not 
participate because the owners re-
fused or were not present. Of the 965 
persons surveyed, 488 (50.6%) were 
male and 476 (49.3%) were female; 
9 (0.9%) had active CL lesions and 
62 (6.4%) had CL scars. One person 
had ML, and 3 had evidence of past 
ML; all ML patients were male. Of 
those with CL lesions, all had 1 lesion 
only. The mean lesion size was 2.3 
cm (range 1.5–3 cm), and the mean 
lesion duration (to survey date) was 
5.6 months (range 1–11 months). The 
clinical CL lesions were parasitologi-
cally conﬁ  rmed by microscopy (n = 4) 
or PCR (n = 8). Parasite culture was 
performed on patient isolates (n = 6), 
and  L.  (V.)  braziliensis was identi-
ﬁ  ed and characterized as the etiologic 
agent of these CL cases.
Active lesion and scar preva-
lence were associated with male sex 
(lesions: Fisher exact test, odds ratio 
[OR] = 7.90 [95% conﬁ  dence inter-
val (CI) 1.01–169.09], p<0.05; scars: 
Yates-corrected  χ2 test, OR = 3.05 
[95% CI 1.65–5.71], p<0.001). Chil-
dren <15 years of age were at lower 
risk of contracting the disease than 
those >15 years (lesions: Fisher exact 
test, OR = 0.19 [95% CI 0.01–1.46], 
p = 0.094; scars: Yates-corrected χ2 
test, OR = 0.09 [95% CI 0.03–0.27], 
p<0.001) (Figure). Active lesion and 
scar prevalence were also associ-
ated with prolonged migration into 
the forest before the survey (lesions: 
Fisher exact test, OR = 28.10 [95% CI 
3.49–184.29], p<0.01; scars: Fisher 
exact test, OR = 35.76 [95% CI 13.49–
93.53], p<0.001).
Whether the surveyed population 
is representative of the total population 
living in the study area is debatable. 
However on the basis of current popu-
lation  ﬁ   gures (i.e., 16,000) and ob-
served prevalence of CL, we estimate 
up to 1,440 CL cases in Isiboro-Secure 
currently. The low prevalence of ac-
tive disease and scars indicates that L. 
(V.)  braziliensis was introduced into 
Isiboro-Secure fairly recently, which 
is corroborated by the short median 
time since the cure of persons with CL 
scars (i.e., 7.5 years, range 0.4–30.5 
years). Combined with the association 
of CL with male sex, age, and migra-
tion to the forest, we conclude that in 
Isiboro-Secure, most L.  (V.)  brazil-
iensis transmission is sylvatic rather 
than peridomestic. This transmission 
pattern implies that prevention and 
control approaches that focus on the 
person (e.g., use of repellents, early 
treatment seeking) will most likely be 
more effective than approaches that 
focus on the household (e.g., indoor 
residual spraying with insecticides, 
insecticide-treated bednets).
Current analyses are underway 
to establish CL risk factors. Addition-
ally, a prevention and control strategy 
adapted to the local context is being 
planned to minimize the population’s 
exposure to sandﬂ  ies, prepare health 
professionals for adequate (per pro-
tocol) management of cases, and 
minimize the likelihood that L.  (V.) 
braziliensis transmission becomes 
peridomestic.
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Figure. Age prevalence curve of persons with lesions (white bars) and scars (black line) 
from cutaneous leishmaniasis, Bolivia, 2007.
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Erratum—Vol. 15, No. 2
The name of Vasanthi Thevanesam should have been included in the author list for the article Severe Den-
gue Epidemics in Sri Lanka, 2003–2006 (N. Kanakaratne et al.). Prof Thevanesam is afﬁ  liated with the Univer-
sity of Peradeniya Faculty of Medicine, Peradeniya, Sri Lanka. The article has been corrected online (www.cdc.
gov/eid/content/15/2/192.htm).
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